HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AVE2268

Antidiabetic; an orally active and selective inhibitor of sodium-dependent glucose transporter 2

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - AVE2268: 3

Experts

1.	Beckers, Johannes: 1 article (01/2015)
2.	Hrabé de Angelis, Martin: 1 article (01/2015)
3.	Huypens, Peter: 1 article (01/2015)
4.	Neschen, Susanne: 1 article (01/2015)
5.	Rathkolb, Birgit: 1 article (01/2015)
6.	Scheerer, Markus: 1 article (01/2015)
7.	Schultheiss, Jürgen: 1 article (01/2015)
8.	Seelig, Anett: 1 article (01/2015)
9.	Suhre, Karsten: 1 article (01/2015)
10.	Wolf, Eckhard: 1 article (01/2015)

Related Diseases

1.	Hyperglycemia 01/01/2015 - "We compared the potential of metformin and the SGLT2I AVE2268 alone or in combination to mitigate hyperglycemia and modulate glucose fluxes in db/db and diabetic Tallyho/JngJ mice. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2008 - "This profile renders AVE2268 as a new antidiabetic drug for the treatment of type 2 diabetes."
3.	Body Weight (Weight, Body) 04/01/2013 - "An almost body weight-neutral antihyperglycaemic treatment could be achieved with AVE2268 and lixisenatide. "

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Hypoglycemic Agents (Hypoglycemics)
3.	Glucose (Dextrose)
4.	lixisenatide